Compare ClearPoint Neuro Inc (CLPT) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Boston Beer Company Inc — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Boston Beer Company Inc trades at $168.61 (market cap $1.76B). The key difference: Boston Beer Company Inc is far larger — about 3.7× ClearPoint Neuro Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | SAM | |
|---|---|---|
Market Cap | $478.63M | $1.76B |
Sector | Health | Consumer Staples |
52-Week High | $29.60 | $260.05 |
52-Week Low | $8.66 | $161.08 |
Enterprise Value | $506.63M | $1.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Boston Beer Company (SAM) trades at $172.39, down 2.49% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, but faces headwinds with negative 2026 profit margin projections. Recent news highlights innovation in Beyond Beer products and marketing initiatives, though Q1 2026 earnings missed expectations and volume growth concerns persist.
The stock presents a cautious opportunity with analyst consensus target of $213.50 offering 24% upside, but investors face risks from declining volumes, margin pressure, and competitive threats. While cash flow remains positive and valuation ratios appear reasonable, the negative 2026 earnings outlook and bearish technical momentum warrant careful monitoring of upcoming Q2 results and brand performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
